Gotham Asset Management LLC Increases Stock Position in Danaher Corporation $DHR

Key Points

• Gotham Asset Management LLC increased its stake in Danaher Corporation by 29.0%, now owning 73,602 shares valued at approximately $15,088,000 after purchasing an additional 16,559 shares.
• Several large investors have made significant changes to their positions in Danaher, including GHP Investment Advisors, which boosted its holdings by 396.0%.
• Danaher reported a net margin of 14.21% and earnings per share of $1.80 for the last quarter, exceeding analysts' expectations with revenues of $5.94 billion.

Gotham Asset Management LLC increased its position in Danaher Corporation (NYSE:DHR - Free Report) by 29.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 73,602 shares of the conglomerate's stock after acquiring an additional 16,559 shares during the quarter. Gotham Asset Management LLC's holdings in Danaher were worth $15,088,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after acquiring an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Danaher by 3.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after purchasing an additional 612,154 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after purchasing an additional 194,466 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Danaher by 11.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after purchasing an additional 579,046 shares during the last quarter. Finally, Invesco Ltd. lifted its position in Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Trading Up 1.2%

NYSE:DHR traded up $2.41 during mid-day trading on Thursday, reaching $195.00. 1,033,776 shares of the company's stock traded hands, compared to its average volume of 4,127,595. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90. The firm has a market capitalization of $139.63 billion, a price-to-earnings ratio of 41.50, a PEG ratio of 2.71 and a beta of 0.75. The company has a 50 day moving average price of $201.62 and a 200-day moving average price of $199.15.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period in the prior year, the business earned $1.72 EPS. The company's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's payout ratio is currently 27.23%.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on DHR shares. Wells Fargo & Company dropped their price target on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 23rd. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a report on Friday, July 11th. Barclays restated an "overweight" rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Finally, Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a report on Tuesday, September 2nd. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $246.35.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.